Alnylam Presents New Pre-clinical Data on ALN-AT3 for Treatment of Hemophilia and RBD at ASH
December 09, 2013 at 20:59 PM EST
Alnylam Pharmaceuticals (Nasdaq: ALNY ) announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of
